vimarsana.com

Page 6 - Mantle Cell Lymphoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cord Blood-Derived Treatment Shows Promise in Blood Cancer

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

United statesKaty rezvaniAmerican cancer societyUniversity of texas md anderson cancer centerAmerican cancerHas promising responsesSide effectCancer centerMantle cell lymphoma

BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

San diegoUnited statesWilliamb pearseUniversity of californiaSan diego school of medicineSan diego schoolWilliam pearseMantle cell lymphomaSan diego school of medicine

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

Jennifer crombieRecent updatesFollicular lymphomaMantle cell lymphomaBeyond therapyCart cell therapyHead to trialAxi celTisa celGrade 3 crsLiso celTranscend flTranscend fl trial

Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Peter martinRecent updatesFollicular lymphomaMantle cell lymphomaBeyond settingPatient preferenceCellular therapyClinical factorReal world dataQuality of lifeBispecific antibodyCart cellSequencing therapyCart cell therapy

Patient Factors, Safety, and Long-Term Efficacy Best Inform Treatment Selection Across Hematologic Malignancies

Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.

Michael choiBenjamin heymanAmanda kaganWilliamb pearseUniversity of california san diegoOnclive stateScience summitCalifornia san diegoAdvancements and treatment considerations in hematologic malignanciesTreatment options in chronic lymphocytic leukemiaFda approval of momelotinibMyelofibrosis with anemiaRontline treatment with btk inhibitorsMantle cell lymphomaCart cell therapyPaul cheng

vimarsana © 2020. All Rights Reserved.